Enanta Pharmaceuticals has been granted a patent for macrocyclic compounds that inhibit coronavirus replication. The patent covers pharmaceutical compositions and methods for treating or preventing coronavirus infections. Formula (III) compounds or their salts are claimed for therapeutic use. GlobalData’s report on Enanta Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Enanta Pharmaceuticals Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Enanta Pharmaceuticals, Human telomerase RT biomarker was a key innovation area identified from patents. Enanta Pharmaceuticals's grant share as of April 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

A recently granted patent (Publication Number: US11970502B2) discloses a compound represented by Formula (III) or its pharmaceutically acceptable salt. The patent also covers various methods of using this compound, including treating viral infections and specifically targeting coronavirus infections. The pharmaceutical composition comprising the compound and a carrier or excipient is also claimed in the patent.

Furthermore, the patent outlines methods for treating viral infections, particularly coronavirus infections, by administering the disclosed compound. The methods include oral, subcutaneous, intravenous, or inhalation administration of the compound. Additionally, the patent covers inhibiting viral 3C protease or viral 3CL protease in a subject by administering the compound. The patent specifies the treatment of various strains of coronaviruses, including 229E, NL63, OC43, HKU1, SARS-CoV, and MERS coronavirus, highlighting the broad spectrum of antiviral activity claimed in the patent.

To know more about GlobalData’s detailed insights on Enanta Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies